For years, pharmaceutical commercialization has been built around hindsight.
Brand teams analyzed prescription data, reviewed physician engagement metrics, tracked payer decisions, and adjusted commercial strategy after market dynamics had already begun to unfold.
Artificial intelligence is poised to change that model entirely, according to Trinity, a leader in life sciences commercialization.
Rather than relying primarily on historical performance, commercial organizations are beginning to use AI to simulate how physicians, patients, and payers are likely to behave before critical decisions are made. The shift could fundamentally change everything from launch planning and field engagement to pricing strategy and market access.
"The biggest transformation isn't simply faster analytics," said Jonathan Jenkins, Head of Digital & AI Solutions at Trinity. "AI allows commercial teams to simulate future scenarios rather than just explain past results. That gives organizations the ability to make decisions based on leading indicators instead of waiting for lagging KPIs."
From Dashboards to Digital Twins
While dashboards and business intelligence platforms have helped commercial organizations monitor performance for years, they remain fundamentally retrospective.
A growing number of life sciences companies are now exploring digital twins—AI-powered virtual representations of customers and markets that continuously incorporate clinical, commercial, and real-world data to simulate future outcomes.
According to Amod Athavale, Executive Director and Head of Integrated Insights at Trinity, digital twins create a shared source of truth that enables organizations to evaluate commercial decisions before they play out in the market.
"Digital twins combine real-world research with AI to connect clinical and commercial data into a single, trusted source of truth," Athavale said. "Instead of relying on lagging KPIs, organizations can test market scenarios, refine targeting, optimize messaging, and coordinate field activity using a continuously updated view of each customer."
The Commercial Playbook Isn't Disappearing—It's Becoming Continuous
Artificial intelligence is unlikely to eliminate traditional commercial planning activities such as sales force sizing, physician targeting, or message testing.
Instead, experts say those activities will become far more dynamic.
Athavale believes physician targeting and message optimization will experience the greatest transformation.
"Targeting and message testing are moving away from broad physician segments and static testing toward digital twins that simulate healthcare provider behavior before those insights are validated with physicians and key opinion leaders," he said.
Digital twins also have practical applications for field organizations.
Rather than simply recommending next-best actions, AI can help representatives prepare for conversations before they occur—allowing teams to rehearse calls, anticipate physician objections, and refine messaging based on likely responses.
Sales force sizing, meanwhile, remains constrained by organizational realities and operational complexity. AI is expected to improve the quality of the analytics behind those decisions rather than fundamentally replace them.
The broader shift, Athavale said, is from commercial strategies that live in presentations at headquarters to AI-enabled decision support embedded directly into the daily workflows of field and brand teams.
Making AI Work in Rare Disease
One of the biggest questions surrounding commercial AI involves rare disease, where limited patient populations create inherently sparse datasets.
Traditional machine learning approaches designed for massive datasets often struggle in these environments.
Instead, Trinity applies methods specifically designed for smaller datasets, including Markov Decision Processes that identify next-best actions and sequencing recommendations from limited commercial interactions.
"Rare disease is fundamentally a small-data problem," Jenkins said. "The answer isn't to apply generic machine learning designed for big data. It's to use methodologies that remain transparent while learning from limited but highly relevant interactions."
Generative AI also has a role beyond predictive modeling.
According to Jenkins, AI can function as a research assistant that develops comprehensive physician profiles, allowing commercial teams to approach each healthcare provider interaction with significantly more context.
Why So Many AI Pilots Fail
Despite widespread investment in generative AI, many commercial organizations remain stuck in pilot mode.
Jenkins argues that the problem is rarely the AI model itself.
Instead, organizations frequently underestimate the work required to help AI understand highly specialized pharmaceutical businesses.
"Many commercial organizations have already invested heavily in their data environments," Jenkins said. "They have harmonized data, governed metrics, lakehouses, and modern analytics platforms. Yet when they build AI on top of that infrastructure, they discover the AI doesn't actually understand the business."
The missing component, he says, is what Trinity refers to as the AI Context Layer.
Traditional semantic models were built for human analysts using dashboards and reports.
AI requires additional context that explains business rules, commercial terminology, organizational knowledge, and relationships between data sources.
Without that context, organizations often generate impressive proofs of concept that struggle to deliver reliable commercial recommendations at scale.
As a result, many companies overinvest in disconnected pilots while underinvesting in the foundational architecture needed to support enterprise-wide AI adoption.
Simulating Launch Before Launch
Perhaps the greatest commercial opportunity lies before products ever reach the market.
Digital twins increasingly allow organizations to model launch sequencing, payer dynamics, physician adoption, pricing strategies, and market access decisions before the first prescription is written.
"Companies can simulate different launch scenarios across markets, stress-test access assumptions, and understand how changes in evidence, pricing, or labeling could affect commercial uptake," Athavale said.
Those models continue learning after launch, incorporating new commercial signals and real-world evidence to continuously refine forecasts and recommend course corrections across medical affairs, market access, and commercial teams.
When Organizations Become AI-Ready
Not every pharmaceutical company is ready to move from AI experimentation to AI-enabled commercial decision-making.
According to Jenkins, successful organizations begin with clearly defined business problems—not broad AI initiatives.
Leadership alignment, governance, funding, trusted data, explainability, and adoption planning all need to be in place before AI becomes part of day-to-day commercial operations.
Organizations also need clear feedback mechanisms that measure whether AI recommendations actually influence field behavior and commercial outcomes.
The Next Competitive Advantage
Over the next five years, the companies that gain the greatest commercial advantage from AI may not be those deploying the largest number of AI applications.
Instead, Trinity believes the leaders will be organizations that redesign their commercial operating models around AI-enabled decision-making.
"Winners will build AI-enabled systems of decision-making rather than isolated tools," Athavale said. "They'll treat digital twins as core commercial infrastructure, continuously validating AI-generated insights against real-world physician, patient, and payer feedback while embedding those capabilities directly into everyday commercial workflows."
Organizations that fail to make that transition may continue launching AI pilots, but many of those insights will remain trapped inside headquarters instead of becoming part of how commercial teams operate in the field.
As AI adoption accelerates across life sciences, the competitive advantage may no longer come from collecting more data.
It may come from building systems capable of turning that data into better commercial decisions before competitors even recognize the opportunity.
